SHL Telemedicine Ltd

Latest Results (24.03.2026):

SHL Telemedicine Ltd — First half (Q1–Q2) 2024: SHL reported HY2024 results with total revenues of USD 27.9m (down ~2% on a constant-currency basis versus HY2023), a small positive adjusted EBITDA of USD 0.5m (up from USD 0.3m), and a net loss of USD 3.9m (worse than HY2023 mainly due to lower financial income). Cash and short-term investments were USD 20.3m at June 30, 2024. Management highlighted operational improvements in Germany, growth in adjusted EBITDA in Israel, increased US D2C investment, and leadership changes including a new CEO and chairman.

Revenues

Total revenues were USD 27.9m in HY2024 — down ~2% versus HY2023 on a constant-currency basis (reported decline ~4%). By region: Israel USD 20.9m (stable), Germany USD 6.6m (slight decline), Rest of World USD 0.4m (materially smaller).

Profitability (EBITDA / EBIT)

Adjusted EBITDA rose to USD 0.5m (from USD 0.3m in HY2023 CC). Reported EBITDA was negative USD 0.2m and adjusted EBIT was negative USD 3.2m. Operating loss (EBIT) was USD 3.9m, with depreciation & amortization of USD 3.7m.

Net loss and financial income

Net loss was USD 3.9m in HY2024 versus a net loss of about USD 2.2m in HY2023 (constant-currency). The deterioration was mainly driven by a drop in net financial income to USD 0.5m (vs USD 3.0m in HY2023), partly reflecting a prior-period non‑cash investor-options gain and FX effects.

Cash and cash flow

Cash on hand and short-term cash investments totaled USD 20.3m at June 30, 2024 (down from USD 26.2m at Dec 31, 2023). Operating cash flow improved to negative USD 0.3m (HY2023: negative USD 3.3m).

Regional and operational developments

Management reported adjusted EBITDA in Israel increased by ~4%, and Germany’s operational losses were reduced by approximately USD 1.0m. The company continues cost management efforts in Germany and is expanding service offerings and platform enhancements.

Investments, strategy and leadership

SHL increased investments in US direct-to-consumer (D2C) operations by about USD 0.7m. Leadership changes include the appointment of David Arnon as CEO and Dr. Itamar Offer as chairman, with Ido Neuberger and Nir Rotenberg joining the board. Management noted encouraging preliminary results from a Mayo Clinic randomized study.

Other items

EPS (basic) for HY2024 was a loss of USD 0.24. The company held a conference call and published the Half‑Year Report 2024 and presentation on its website and SEC filings. Results are presented with HY2023 shown on HY2024 exchange rates to reduce currency‑noise; forward‑looking statements and standard risk disclosures apply.